Robert Scott Goodman - 29 Jul 2026 Form 4 Insider Report for Beyond Air, Inc. (XAIR)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: XAIR
Reported as of: 29 Jul 2026
Net transaction value: +$199,999
SEC form: 4
Accepted by SEC: 31 Jul 2026, 18:55:38 UTC
Prior SEC filing: 06 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Scott Goodman

Key filing fact

Robert Scott Goodman filed Form 4 for Beyond Air, Inc. (XAIR) on 31 Jul 2026.

Key facts

This page summarizes Robert Scott Goodman's Form 4 filing for Beyond Air, Inc. (XAIR).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 31 Jul 2026, 18:55.

Change

Previous filing in this sequence was filed on 06 Nov 2025.
Current net transaction value: +$199,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002075668 Primary reporting owner

Goodman Robert Scott

Relationship: Chief Executive Officer, Director
Address: C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY
Signature: /s/ Robert Scott Goodman
Signature date: 31 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XAIR transaction

Common Stock

Purchase

Transaction value: $199,999
Shares: +34,722
Change %: +34722%
Price: $5.76
Shares after: 34,822
Date: 29 Jul 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XAIR transaction Derivative

Series A Warrants

Purchase

Transaction value
Shares: +34,722
Change %
Price
Shares after: 34,722
Date: 29 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,722
Exercise price: $5.51
Footnotes: F1, F2, F3

XAIR transaction Derivative

Series B Warrants

Purchase

Transaction value
Shares: +34,722
Change %
Price
Shares after: 34,722
Date: 29 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,722
Exercise price: $5.51
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Exercisable immediately upon issuance

Footnote F2

Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II

Footnote F3

Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76.

Footnote F4

5 years following date of issuance